Listed

Edwards Lifesciences Corp: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Oct 26, 2020 and accepted by EDGAR at Oct 23, 2020, 19:57 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-07-01 to 2020-09-30$1.14bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-01-01 to 2020-09-30$3.19bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-07-01 to 2020-09-30$281.0mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2020-01-01 to 2020-09-30$784.3mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2020-07-01 to 2020-09-30$859.9mus-gaap:GrossProfit
Gross profit9 months2020-01-01 to 2020-09-30$2.41bnus-gaap:GrossProfit
Research and development3 months2020-07-01 to 2020-09-30$195.5mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-01-01 to 2020-09-30$565.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2020-07-01 to 2020-09-30$307.2mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2020-01-01 to 2020-09-30$889.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-07-01 to 2020-09-30$357.8mus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30$546.2mus-gaap:OperatingIncomeLoss
Income tax3 months2020-07-01 to 2020-09-30$39.1mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2020-01-01 to 2020-09-30$46.7mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-07-01 to 2020-09-30$325.2mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income9 months2020-01-01 to 2020-09-30$513.9mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2020-07-01 to 2020-09-30$0.52us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2020-01-01 to 2020-09-30$0.82us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-07-01 to 2020-09-30$0.52us-gaap:EarningsPerShareBasic
Basic EPS9 months2020-01-01 to 2020-09-30$0.83us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-07-01 to 2020-09-30631,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2020-01-01 to 2020-09-30628,800,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2020-01-01 to 2020-09-30$654.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-30$293.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2020-01-01 to 2020-09-30$625.2mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-09-30$1.02bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$2.98bnus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$6.80bnus-gaap:Assets
Current liabilitiesAt period end2020-09-30$846.3mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2020-09-30$594.9mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2020-09-30$4.21bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001099800-20-000024. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.